drugset
Drugs / VEGFR2
last change Jun 2012 re-read 2 minutes ago

VEGFR2

Peptide targets KDR

Developed for
esophageal cancer · non-small cell lung carcinoma · gastric cancer · colon carcinoma · rectal cancer · wet macular degeneration
Investigated by
Human Genome Center, Institute of Medical Science, University of Tokyo · Tokyo University · Fukushima Medical University · Japanese Foundation for Cancer Research · Osaka University · Teikyo University

Trials 10 · a red edge is where a trial was stopped

today NCT00874588 · Ph 1 NCT00791570 · Ph 1 NCT00681577 · Ph 1/2 NCT00677287 · Ph 1/2 NCT00681421 · Ph 1/2 NCT00681252 · Ph 1/2 NCT00673777 · Ph 1/2 NCT00632333 · Ph 1 NCT00561275 · Ph 1 NCT00633724 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT00874588 Mar 2009 → Jun 2012 non-small cell lung carcinoma Fukushima Medical University Completed No outcome recorded
Phase 1 NCT00791570 Oct 2008 → Apr 2012 wet macular degeneration Osaka University Completed No outcome recorded
Phase 1 NCT00632333 Feb 2008 → Dec 2011 esophageal cancer Teikyo University Unknown No outcome recorded
Phase 1 NCT00561275 Oct 2007 → May 2008 esophageal cancer Japanese Foundation for Cancer Research Completed No outcome recorded
Phase 1 NCT00633724 May 2007 → Jun 2012 non-small cell lung carcinoma Fukushima Medical University Completed No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT00681577 May 2008 → Oct 2009 gastric cancer Tokyo University Completed No outcome recorded
Phase 1/2 NCT00677287 May 2008 → Mar 2009 colon carcinoma, rectal cancer Tokyo University Terminated No outcome recorded
Phase 1/2 NCT00681421 May 2008 → Apr 2009 esophageal cancer Tokyo University Completed No outcome recorded
Phase 1/2 NCT00681252 May 2008 → Apr 2009 gastric cancer Tokyo University Completed No outcome recorded
Phase 1/2 NCT00673777 May 2008 → Apr 2009 non-small cell lung carcinoma Tokyo University Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as VEGFR2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00561275 ↗
9

NCT00633724 ↗

NCT00677287 ↗

NCT00791570 ↗

NCT00673777 ↗

NCT00681421 ↗

NCT00632333 ↗

NCT00874588 ↗

NCT00681252 ↗

NCT00681577 ↗
Modality Peptide “VEGFR2 peptide(1mg)” NCT00673777 ↗
Route Subcutaneous “the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection” NCT00681252 ↗
Target VEGFR2 “Vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) are essential targets for tumor angiogenesis.” NCT00632333 ↗